- US-listed companies
- Panbela Therapeutics, Inc.
- Income statement
Panbela Therapeutics, Inc.【PBLA】Income statement
Market cap
$63.36K
P/E ratio
| 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | |
| Revenue | 1 | 973,813 | 1 | - | - | - | - | - | - | - | - | - |
| Revenue growth (%) | - | - | - | - | - | - | - | - | - | - | ||
| Cost of revenue | 691,802 | 558,465 | 595,152 | - | - | - | - | - | - | - | - | - |
| Gross profit | 540,902 | 415,348 | 761,843 | - | - | - | - | - | - | - | - | - |
| Gross margin (%) | - | - | - | - | - | - | - | - | - | |||
| Research & development | - | 279,791 | - | 3 | 3 | 3 | 2 | 2 | 3 | 5 | 28 | 21 |
| Operating margin (%) | - | - | - | - | - | - | - | - | - | |||
| Operating expenses | - | 609,670 | - | - | - | - | - | - | - | - | - | - |
| Operating income | 282,804 | -194,322 | -75,398 | -5 | -5 | -6 | -4 | -4 | -6 | -10 | -34 | -26 |
| Income before tax | - | - | - | -6 | -5 | -11 | -6 | -7 | -5 | -11 | -35 | -25 |
| Provision for income taxes | 284 | 220 | 121 | -1 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 |
| Effective tax rate (%) | - | - | - | |||||||||
| Net income | 247,380 | -212,021 | -107,044 | -5 | -5 | -10 | 35 | -6 | -5 | -10 | -35 | -25 |
| Net income margin (%) | - | - | - | - | - | - | - | - | - | |||
| Earnings per share | 0.17 | -0.15 | - | - | - | - | - | - | - | - | -67.91 | -316.52 |
| Diluted EPS | 0.17 | -0.15 | - | - | - | - | - | - | - | - | -67.91 | -316.52 |